Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
International Journal of Hematology
Erschienen in:

11.05.2020 | Original Article

Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera

verfasst von: Norio Komatsu, GyungJin Jun, Toshio Yonezu, Yasuo Ohashi

Erschienen in: International Journal of Hematology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

In this retrospective, real-world study, we used medical claims data to evaluate the incidence of thromboembolic events (TEs), time to TE, associated risk factors, and health-care resource utilization (HRU) in Japanese patients with polycythemia vera (PV; N = 606) from April 1, 2008, to August 31, 2015. Baseline characteristics of interest included median age, 67.0 years; previous TEs, 11.6%; cardiovascular conditions (CVCs), 45.7%; and ≥ 3 risk factors, 17.8%. Overall, 100 patients experienced TEs (118 events) at a rate of 8.15/100 person-years [TE-free survival rate, 69.3% (2008–2015)]. The annual total health-care costs [mean (per person)] were significantly impacted by the presence of TEs (yes vs. no: ¥993,000 vs ¥459,000; P < 0.001). These results confirm that the presence of CVCs increases the risk of TEs in Japanese patients with PV; occurrence of TEs was associated with a higher HRU in these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14:609–17.CrossRef
2.
Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–90.CrossRef
3.
Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008;22:1494–502.CrossRef
4.
Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901–10.CrossRef
5.
Stein BL, Oh ST, Berenzon D, Hobbs SG, Kremyanskaya M, Rampal RK, et al. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol. 2015;33:3953–60.CrossRef
6.
Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009;43:81–7.CrossRef
7.
Spivak JL. Narrative review: thrombocytosis, polycythemia vera, and JAK2 mutations: the phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 2010;152:300–6.CrossRef
8.
Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–83.CrossRef
9.
Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol. 2016;34:151–9.CrossRef
10.
Paranagama D, Colucci P, Evans KA, Bonafede M, Parasuraman S. Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. Exp Hematol Oncol. 2018;7:16.CrossRef
11.
Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2016;5:3.CrossRef
12.
Kamiunten A, Shide K, Kameda T, Sekine M, Kubuki Y, Ito M, et al. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. Int J Hematol. 2018;107:681–8.CrossRef
13.
Raedler LA. Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits. 2015;8(Spec Feature):75–9.PubMedPubMedCentral
14.
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.CrossRef
15.
Raedler LA. Diagnosis and management of polycythemia vera. Proceedings from a multidisciplinary roundtable. Am Health Drug Benefits. 2014;7(7 suppl 3):S36–S47.PubMedPubMedCentral
16.
Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015;29:215–21.CrossRef
17.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.CrossRef
18.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.CrossRef
19.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.CrossRef
20.
Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071–82.CrossRef
21.
Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443–9.CrossRef
22.
Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):16–211.CrossRef
23.
Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656–64.CrossRef
24.
Pearson TC. Haemorheological considerations in the pathogenesis of vascular occlusive events in polycythaemia vera. Sem Thromb Hemost. 1997;23:433–9.CrossRef
25.
Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219–22.CrossRef
26.
Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19:184.CrossRef
27.
Radia D, Geyer HL. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematol Am Soc Hematol Educ Program. 2015;2015:340–8.CrossRef
28.
Vannucchi AM, Barbui T. Thrombocytosis and thrombosis. Hematol Am Soc Hematol Educ Program. 2007;2007:363–70.CrossRef
29.
Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014;55:2368–74.CrossRef
30.
Gorog DA, Yamamoto J, Saraf S, Ishii H, Ijiri Y, Ikarugi H, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the “Japanese paradox”. Int J Cardiol. 2011;152:43–8.CrossRef
31.
Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, et al. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res. 2016;40:68–766.CrossRef
32.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.CrossRef
33.
Hultcrantz M, Andersson TML, Landgren O, Derolf AR, Dickman PW, Björkholm M, et al. Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls; a population-based study. Blood. 2014;124:632.CrossRef
34.
Grunwald MR, Stein BL, Boccia RV, Oh ST, Paranagama D, Parasuraman S, et al. Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(788–95):e2.
35.
Stein BL, Naim A, Grunwald MR, Moliterno AR, Oh ST, Paranagama D, et al. Examining the clinical features and underlying cardiovascular risk among patients with polycythemia vera in the REVEAL study. Blood. 2016;128:1934.CrossRef
36.
Durmus A, Mentese A, Yilmaz M, Sumer A, Akalin I, Topal C, et al. The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. Med Princ Pract. 2014;23:253–8.CrossRef
Metadaten
Titel
Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera
verfasst von
Norio Komatsu
GyungJin Jun
Toshio Yonezu
Yasuo Ohashi
Publikationsdatum
11.05.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 2/2020
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02887-w

Weitere Artikel der Ausgabe 2/2020

Characterization of hereditary factor XI deficiency in Taiwanese patients: identification of three novel and two common mutations

  • Original Article

Testicular plasmacytoma in a patient with relapsed multiple myeloma

  • Images in Hematology

Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice

  • Original Article

Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation

  • Original Article

The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse

  • Original Article

Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience

  • Original Article

Neu im Fachgebiet Onkologie

Dänische Zwillingsstudie deutet auf erhöhtes Krebsrisiko bei Tätowierten hin

Haben Tattoo-Träger und -Trägerinnen ein erhöhtes Risiko, an Hautkrebs oder einem Lymphom zu erkranken? Die Ergebnisse einer Zwillingsstudie aus Dänemark scheinen dafür zu sprechen. Die Forschungsgruppe rät vorerst zur Zurückhaltung beim Tätowieren.

Weniger PSA-Screening, mehr fortgeschrittene Tumoren

Eine Empfehlung gegen das Prostatakrebs-Screening, die mehrere Jahre in den Leitlinien des Royal Australasian College of General Practitioners gegeben wurde, hat sich nicht nur auf die Rate von PSA-Tests negativ ausgewirkt.

Schützt kutane Autoimmunität vor Hauttumoren?

Schwedische Registerdaten deuten auf ein geringeres Risiko für bestimmte Hauttumoren bei Personen mit Vitiligo oder autoimmuner Alopezie. Wie es dazu kommt, ist dagegen unklar.

Muss man wirklich auch die letzte Krebszelle eliminieren?

Genauere Prognoseabschätzung, bessere Therapiesteuerung und eine schnellere Entwicklung innovativer Behandlungsansätze – der Messung der minimalen Resterkrankung (MRD) wird ein enormes Potenzial attestiert. Eine Übersichtsarbeit unterstreicht jetzt aber: Es gibt noch blinde Flecken.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise